3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Uveal Melanoma
2
Retinoblastoma
1
Retinal Diseases
1
Melanoma
1
Macular Degeneration
1
Choroid Diseases
1
Interventions
Nivolumab
25
pembrolizumab
20
Ipilimumab
15
toripalimab
12
Temozolomide
11
Biopsy
8
Dacarbazine
7
Cyclophosphamide
6
Blood Specimen Collection
6
trametinib
5
fludarabine
5
dabrafenib
5
camrelizumab
5
atezolizumab
5
Gene Expression Profiling
5
Chemotherapy, Adjuvant
5
durvalumab
4
binimetinib
4
aldesleukin
4
Interleukin-2
4
Injections
4
Carboplatin
4
tislelizumab
3
palbociclib
3
encorafenib
3
apatinib
3
Sorafenib
3
Paclitaxel
3
Introns
3
Drug Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Melanoma
×
Ranibizumab
×
Clear all
NCT00811200
2009-07-02
TORR
Leiden University Medical Center
Phase 2/3
Unknown
220 enrolled